Good morning :)
Place Order
Add to Watchlist

Beta Drugs Ltd

BETA

Beta Drugs Ltd

BETA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,869 cr, stock is ranked 1,175
High RiskStock is 3.65x as volatile as Nifty
1,979.901.84% (+35.75)
1,979.901.84% (+35.75)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,869 cr, stock is ranked 1,175
High RiskStock is 3.65x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,869 cr, stock is ranked 1,175
High RiskStock is 3.65x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
11.90
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.236.550.51%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Beta Drugs Limited is a pharmaceutical formulation manufacturing company. It is engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Company also engaged manufacturing oncology products

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 34.98%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.03% to 0.08%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 35.28%, vs industry avg of 15.28%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue50.8166.3091.22116.62184.60227.86297.07
Raw Materialssubtract28.1537.2645.2160.5596.21110.40167.65
Power & Fuel Costsubtract0.891.211.952.753.434.796.35
Employee Costsubtract1.263.806.958.3212.1017.0820.14
Selling & Administrative Expensessubtract4.857.8210.2710.3116.2625.8933.12
Operating & Other expensessubtract5.964.048.529.4513.1415.838.46
Depreciation/Amortizationsubtract1.852.843.766.877.2510.419.78
Interest & Other Itemssubtract1.011.432.592.421.902.412.82
Taxes & Other Itemssubtract0.07-0.142.564.239.4810.3412.32
EPS7.839.3010.3012.1925.8331.9437.89
DPS0.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Beta Drugs Ltd51.3111.90
Sun Pharmaceutical Industries Ltd45.196.450.75%
Cipla Ltd31.374.820.81%
Mankind Pharma Ltd56.8511.36

Price Comparison

Compare BETA with any stock or ETF
Compare BETA with any stock or ETF
BETA
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding66.73%0.00%0.12%0.90%32.25%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun0.29%0.29%0.32%0.32%0.32%0.90%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

BETA has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2024Powered by Capital Market - Live

1 day agoCapital Market - Live
Corporate
Beta Drugs to conduct EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 12 November 2024 .Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Beta Drugs schedules AGM

Beta Drugs announced that the 19th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Stock market update: Stocks that hit 52-week highs on NSE

1 year agoEconomic Times
बढ़ने और गिरने वाले SME's शेयर: Bright Solar, Nitiraj Engineers, Omfurn India, Beta Drugs
5 years agoCNBC Awaaz